 Kathryn Colborn
Concepts (403)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 10 | 2023 | 829 | 3.110 |
Why?
| | Postoperative Complications | 28 | 2023 | 2235 | 2.530 |
Why?
| | Quality Improvement | 14 | 2023 | 963 | 1.480 |
Why?
| | Machine Learning | 7 | 2023 | 331 | 1.430 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 136 | 1.430 |
Why?
| | Sepsis | 6 | 2023 | 531 | 1.430 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 215 | 1.380 |
Why?
| | Shock, Septic | 4 | 2023 | 187 | 1.320 |
Why?
| | Malaria | 4 | 2023 | 60 | 1.190 |
Why?
| | Surgical Wound Infection | 5 | 2023 | 251 | 0.990 |
Why?
| | Pancreatic Neoplasms | 7 | 2023 | 734 | 0.940 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 79 | 0.880 |
Why?
| | Models, Statistical | 4 | 2020 | 636 | 0.870 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 31 | 0.840 |
Why?
| | Retrospective Studies | 40 | 2023 | 12978 | 0.830 |
Why?
| | Artificial Intelligence | 1 | 2023 | 140 | 0.820 |
Why?
| | Humans | 108 | 2024 | 118974 | 0.770 |
Why?
| | Plasmodium vivax | 2 | 2018 | 6 | 0.760 |
Why?
| | Malaria, Vivax | 2 | 2018 | 6 | 0.760 |
Why?
| | Pain | 2 | 2023 | 735 | 0.740 |
Why?
| | Pneumonia | 3 | 2023 | 592 | 0.690 |
Why?
| | Inpatients | 4 | 2023 | 388 | 0.680 |
Why?
| | Poisson Distribution | 1 | 2018 | 68 | 0.630 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 34 | 0.630 |
Why?
| | Health Plan Implementation | 1 | 2019 | 133 | 0.620 |
Why?
| | Risk Assessment | 15 | 2023 | 3057 | 0.610 |
Why?
| | Databases, Factual | 12 | 2023 | 1231 | 0.610 |
Why?
| | Hospitalization | 6 | 2021 | 1785 | 0.600 |
Why?
| | Mosquito Control | 2 | 2023 | 25 | 0.580 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 210 | 0.550 |
Why?
| | Risk Factors | 22 | 2023 | 9000 | 0.540 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.540 |
Why?
| | Palliative Care | 6 | 2023 | 629 | 0.530 |
Why?
| | Anopheles | 1 | 2015 | 16 | 0.530 |
Why?
| | Surgeons | 3 | 2023 | 243 | 0.500 |
Why?
| | Drug Prescriptions | 3 | 2021 | 248 | 0.490 |
Why?
| | Breast Neoplasms | 5 | 2023 | 1965 | 0.470 |
Why?
| | Middle Aged | 29 | 2023 | 27617 | 0.470 |
Why?
| | Female | 43 | 2023 | 61565 | 0.450 |
Why?
| | Patient Discharge | 2 | 2020 | 796 | 0.440 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 50 | 0.440 |
Why?
| | Hospital Mortality | 1 | 2016 | 814 | 0.420 |
Why?
| | Adult | 28 | 2023 | 31512 | 0.420 |
Why?
| | Thoracic Surgery | 2 | 2023 | 120 | 0.420 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 67 | 0.410 |
Why?
| | Male | 38 | 2023 | 57801 | 0.410 |
Why?
| | Quality of Life | 8 | 2024 | 2366 | 0.400 |
Why?
| | Algorithms | 4 | 2019 | 1541 | 0.400 |
Why?
| | Primary Health Care | 2 | 2019 | 1560 | 0.400 |
Why?
| | Aged | 21 | 2023 | 19657 | 0.400 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 417 | 0.380 |
Why?
| | Neoadjuvant Therapy | 6 | 2023 | 333 | 0.380 |
Why?
| | Influenza, Human | 3 | 2021 | 554 | 0.380 |
Why?
| | Patient Reported Outcome Measures | 5 | 2024 | 252 | 0.370 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2023 | 240 | 0.360 |
Why?
| | Emergency Treatment | 2 | 2021 | 110 | 0.350 |
Why?
| | Child, Preschool | 13 | 2023 | 9491 | 0.350 |
Why?
| | Hospitals | 3 | 2022 | 598 | 0.320 |
Why?
| | Research Design | 3 | 2022 | 969 | 0.320 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 223 | 0.310 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 323 | 0.300 |
Why?
| | Logistic Models | 5 | 2023 | 1901 | 0.300 |
Why?
| | Incidence | 6 | 2020 | 2424 | 0.300 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 247 | 0.300 |
Why?
| | Aged, 80 and over | 9 | 2023 | 6561 | 0.290 |
Why?
| | Chagas Disease | 2 | 2018 | 34 | 0.290 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 121 | 0.290 |
Why?
| | Cohort Studies | 10 | 2023 | 5116 | 0.290 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.290 |
Why?
| | Adenocarcinoma | 2 | 2023 | 812 | 0.280 |
Why?
| | Colorado | 7 | 2021 | 4196 | 0.280 |
Why?
| | Asthma | 1 | 2019 | 2158 | 0.270 |
Why?
| | United States | 15 | 2023 | 12555 | 0.260 |
Why?
| | Heart Failure | 4 | 2018 | 1969 | 0.250 |
Why?
| | Emergency Service, Hospital | 3 | 2020 | 1865 | 0.250 |
Why?
| | Young Adult | 11 | 2020 | 10793 | 0.240 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 794 | 0.240 |
Why?
| | Metastasectomy | 1 | 2023 | 12 | 0.230 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1868 | 0.230 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 34 | 0.230 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 42 | 0.230 |
Why?
| | Specialties, Surgical | 2 | 2021 | 76 | 0.230 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 31 | 0.220 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1200 | 0.220 |
Why?
| | Insecticides | 1 | 2023 | 31 | 0.220 |
Why?
| | Europe | 1 | 2023 | 356 | 0.220 |
Why?
| | Thoracic Surgical Procedures | 1 | 2023 | 64 | 0.220 |
Why?
| | Microcephaly | 1 | 2023 | 54 | 0.220 |
Why?
| | Carotid Stenosis | 1 | 2023 | 75 | 0.220 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1474 | 0.220 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 57 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 61 | 0.220 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 62 | 0.220 |
Why?
| | Risk Adjustment | 1 | 2023 | 79 | 0.220 |
Why?
| | Adolescent | 13 | 2023 | 18480 | 0.220 |
Why?
| | Pain, Postoperative | 2 | 2021 | 211 | 0.220 |
Why?
| | Polypharmacy | 1 | 2023 | 75 | 0.210 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 40 | 0.210 |
Why?
| | Robotic Surgical Procedures | 1 | 2024 | 89 | 0.210 |
Why?
| | Medication Therapy Management | 1 | 2023 | 72 | 0.210 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 83 | 0.210 |
Why?
| | Delirium | 1 | 2023 | 70 | 0.210 |
Why?
| | Galectins | 1 | 2022 | 23 | 0.210 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 83 | 0.210 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 42 | 0.210 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2023 | 360 | 0.210 |
Why?
| | Ivermectin | 1 | 2021 | 10 | 0.200 |
Why?
| | Mozambique | 2 | 2018 | 5 | 0.200 |
Why?
| | Preoperative Care | 2 | 2021 | 332 | 0.200 |
Why?
| | Knee Joint | 2 | 2021 | 353 | 0.200 |
Why?
| | Prognosis | 7 | 2023 | 3443 | 0.200 |
Why?
| | Mastectomy, Segmental | 1 | 2021 | 91 | 0.200 |
Why?
| | Dysbiosis | 1 | 2022 | 147 | 0.190 |
Why?
| | Intensive Care Units | 2 | 2022 | 635 | 0.190 |
Why?
| | Program Evaluation | 3 | 2021 | 845 | 0.190 |
Why?
| | Oxycodone | 1 | 2021 | 45 | 0.190 |
Why?
| | Gastric Bypass | 1 | 2022 | 93 | 0.190 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.190 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 21 | 0.190 |
Why?
| | Terminal Care | 1 | 2023 | 187 | 0.190 |
Why?
| | Arthroplasty | 1 | 2020 | 52 | 0.180 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 38 | 0.180 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 252 | 0.180 |
Why?
| | Faculty | 1 | 2021 | 135 | 0.180 |
Why?
| | Artemisinins | 1 | 2019 | 2 | 0.180 |
Why?
| | Infant | 8 | 2023 | 8293 | 0.180 |
Why?
| | Antimalarials | 1 | 2019 | 24 | 0.180 |
Why?
| | General Surgery | 1 | 2021 | 134 | 0.180 |
Why?
| | Rural Population | 2 | 2020 | 452 | 0.180 |
Why?
| | Hypersensitivity | 1 | 2023 | 268 | 0.180 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 234 | 0.170 |
Why?
| | Waiting Lists | 2 | 2021 | 228 | 0.170 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 128 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2021 | 165 | 0.170 |
Why?
| | Prisons | 1 | 2010 | 74 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 227 | 0.170 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 59 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2022 | 197 | 0.170 |
Why?
| | Treatment Outcome | 9 | 2023 | 9342 | 0.170 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 69 | 0.170 |
Why?
| | Laparoscopy | 1 | 2023 | 417 | 0.170 |
Why?
| | Outpatients | 1 | 2022 | 325 | 0.170 |
Why?
| | Cognition | 2 | 2023 | 1024 | 0.170 |
Why?
| | Burns | 1 | 2022 | 247 | 0.170 |
Why?
| | Aftercare | 1 | 2020 | 194 | 0.170 |
Why?
| | Zebrafish | 1 | 2022 | 434 | 0.170 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 461 | 0.170 |
Why?
| | Condoms, Female | 1 | 2008 | 6 | 0.160 |
Why?
| | Quinolines | 1 | 2019 | 128 | 0.160 |
Why?
| | Datasets as Topic | 1 | 2019 | 103 | 0.160 |
Why?
| | Triage | 1 | 2021 | 203 | 0.160 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 30 | 0.160 |
Why?
| | Social Marketing | 1 | 2008 | 14 | 0.160 |
Why?
| | Community Participation | 1 | 2019 | 120 | 0.160 |
Why?
| | Reproductive Medicine | 1 | 2008 | 13 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 126 | 0.160 |
Why?
| | Autistic Disorder | 1 | 2020 | 168 | 0.160 |
Why?
| | Hospitals, University | 1 | 2018 | 172 | 0.160 |
Why?
| | Developed Countries | 1 | 2018 | 32 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 199 | 0.160 |
Why?
| | Ventricular Function | 1 | 2018 | 60 | 0.160 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 299 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 73 | 0.160 |
Why?
| | Computers, Handheld | 1 | 2018 | 25 | 0.160 |
Why?
| | ROC Curve | 1 | 2019 | 473 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 387 | 0.160 |
Why?
| | Patient Admission | 1 | 2019 | 176 | 0.160 |
Why?
| | Climate | 1 | 2018 | 91 | 0.160 |
Why?
| | Population Groups | 1 | 2018 | 58 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2019 | 174 | 0.160 |
Why?
| | Geography | 1 | 2018 | 190 | 0.150 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 39 | 0.150 |
Why?
| | Occupational Health | 1 | 2010 | 172 | 0.150 |
Why?
| | Safety-net Providers | 1 | 2019 | 96 | 0.150 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 80 | 0.150 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 118 | 0.150 |
Why?
| | Recovery of Function | 1 | 2021 | 604 | 0.150 |
Why?
| | Condoms | 1 | 2008 | 110 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 537 | 0.150 |
Why?
| | Child | 10 | 2023 | 19129 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 304 | 0.150 |
Why?
| | Epidemics | 1 | 2018 | 70 | 0.150 |
Why?
| | Lymph Node Excision | 3 | 2023 | 158 | 0.150 |
Why?
| | Anxiety Disorders | 1 | 2010 | 309 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2010 | 277 | 0.150 |
Why?
| | Gastroenteritis | 1 | 2017 | 64 | 0.150 |
Why?
| | Cell Phone | 1 | 2017 | 81 | 0.140 |
Why?
| | Students, Medical | 1 | 2021 | 311 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 446 | 0.140 |
Why?
| | Influenza Vaccines | 1 | 2021 | 500 | 0.140 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 67 | 0.140 |
Why?
| | Nurse Practitioners | 1 | 2018 | 107 | 0.140 |
Why?
| | Alcoholism | 1 | 2023 | 717 | 0.140 |
Why?
| | Patient Readmission | 2 | 2020 | 634 | 0.140 |
Why?
| | Mass Screening | 2 | 2020 | 1052 | 0.140 |
Why?
| | Fever | 1 | 2017 | 283 | 0.140 |
Why?
| | Melanoma | 1 | 2022 | 664 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 102 | 0.140 |
Why?
| | Forecasting | 1 | 2018 | 353 | 0.140 |
Why?
| | Cannabidiol | 1 | 2016 | 53 | 0.140 |
Why?
| | Morbidity | 3 | 2022 | 296 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 338 | 0.130 |
Why?
| | Healthcare Disparities | 2 | 2018 | 496 | 0.130 |
Why?
| | Models, Organizational | 1 | 2016 | 146 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2019 | 542 | 0.130 |
Why?
| | Mobile Applications | 1 | 2017 | 147 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2022 | 762 | 0.130 |
Why?
| | Humidity | 1 | 2015 | 45 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1390 | 0.130 |
Why?
| | Advance Care Planning | 1 | 2018 | 191 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 765 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2016 | 184 | 0.130 |
Why?
| | Diarrhea | 3 | 2023 | 181 | 0.130 |
Why?
| | Massage | 2 | 2010 | 44 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1047 | 0.120 |
Why?
| | Chronic Pain | 1 | 2018 | 211 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2018 | 405 | 0.120 |
Why?
| | Family Practice | 1 | 2018 | 438 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1795 | 0.120 |
Why?
| | Models, Biological | 1 | 2021 | 1715 | 0.120 |
Why?
| | Parasitemia | 1 | 2013 | 9 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 703 | 0.120 |
Why?
| | Indians, North American | 1 | 2009 | 598 | 0.120 |
Why?
| | Emergency Medical Services | 1 | 2021 | 589 | 0.120 |
Why?
| | Software | 1 | 2018 | 613 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2020 | 968 | 0.110 |
Why?
| | Prospective Studies | 5 | 2024 | 6471 | 0.110 |
Why?
| | Research | 1 | 2016 | 411 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1244 | 0.110 |
Why?
| | Medicaid | 1 | 2017 | 411 | 0.110 |
Why?
| | Epilepsy | 1 | 2016 | 290 | 0.110 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 253 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 485 | 0.110 |
Why?
| | Temperature | 1 | 2015 | 622 | 0.110 |
Why?
| | Axilla | 2 | 2023 | 57 | 0.110 |
Why?
| | Prevalence | 3 | 2023 | 2326 | 0.100 |
Why?
| | Feedback | 2 | 2023 | 153 | 0.100 |
Why?
| | Pain Management | 2 | 2010 | 294 | 0.100 |
Why?
| | Mastectomy | 2 | 2023 | 124 | 0.100 |
Why?
| | Patients | 2 | 2023 | 175 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2490 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 2995 | 0.100 |
Why?
| | Uganda | 2 | 2023 | 74 | 0.100 |
Why?
| | Internship and Residency | 1 | 2021 | 1001 | 0.100 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 307 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2017 | 671 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2220 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1974 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 664 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 97 | 0.090 |
Why?
| | Postoperative Period | 2 | 2021 | 309 | 0.090 |
Why?
| | Guatemala | 2 | 2023 | 296 | 0.090 |
Why?
| | Pandemics | 3 | 2023 | 1355 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2015 | 601 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2016 | 867 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2023 | 455 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 4708 | 0.080 |
Why?
| | Seasons | 2 | 2020 | 461 | 0.080 |
Why?
| | Survival Rate | 2 | 2023 | 1720 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1125 | 0.080 |
Why?
| | Referral and Consultation | 2 | 2023 | 648 | 0.080 |
Why?
| | Comorbidity | 2 | 2022 | 1527 | 0.080 |
Why?
| | Immunization Programs | 1 | 2009 | 206 | 0.070 |
Why?
| | Length of Stay | 2 | 2023 | 1032 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4596 | 0.070 |
Why?
| | Urban Population | 2 | 2020 | 409 | 0.070 |
Why?
| | School Health Services | 1 | 2009 | 203 | 0.070 |
Why?
| | Affect | 1 | 2008 | 240 | 0.070 |
Why?
| | Pilot Projects | 2 | 2023 | 1419 | 0.070 |
Why?
| | Insurance Coverage | 2 | 2017 | 208 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 610 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4552 | 0.060 |
Why?
| | Body Mass Index | 2 | 2023 | 2092 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1129 | 0.060 |
Why?
| | Cytokines | 2 | 2023 | 1900 | 0.060 |
Why?
| | Acute Disease | 2 | 2017 | 940 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2010 | 546 | 0.060 |
Why?
| | Community Health Workers | 1 | 2023 | 49 | 0.060 |
Why?
| | Herniorrhaphy | 1 | 2023 | 52 | 0.060 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.060 |
Why?
| | Health Facilities | 1 | 2023 | 75 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1510 | 0.060 |
Why?
| | Growth Disorders | 1 | 2023 | 77 | 0.060 |
Why?
| | Death | 1 | 2023 | 105 | 0.060 |
Why?
| | Biological Variation, Population | 1 | 2022 | 23 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 123 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 28 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 26 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 7 | 0.050 |
Why?
| | Cough | 1 | 2023 | 102 | 0.050 |
Why?
| | Breast | 1 | 2023 | 140 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 37 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2459 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 184 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 97 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2023 | 165 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 164 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 649 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 387 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 51 | 0.050 |
Why?
| | Gastrectomy | 1 | 2022 | 82 | 0.050 |
Why?
| | Demography | 1 | 2022 | 274 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 437 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 133 | 0.050 |
Why?
| | Habits | 1 | 2020 | 38 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 567 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 320 | 0.050 |
Why?
| | Preoperative Period | 1 | 2021 | 110 | 0.050 |
Why?
| | Lung | 2 | 2024 | 3664 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 200 | 0.050 |
Why?
| | Censuses | 1 | 2020 | 19 | 0.050 |
Why?
| | Research Personnel | 1 | 2022 | 158 | 0.050 |
Why?
| | Fear | 1 | 2023 | 307 | 0.050 |
Why?
| | South Africa | 1 | 2021 | 163 | 0.050 |
Why?
| | Reoperation | 1 | 2023 | 557 | 0.050 |
Why?
| | Animals | 3 | 2022 | 33381 | 0.050 |
Why?
| | Schools, Medical | 1 | 2021 | 139 | 0.050 |
Why?
| | Policy | 1 | 2021 | 133 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1166 | 0.050 |
Why?
| | Emergencies | 1 | 2021 | 153 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 248 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 481 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 160 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 39 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 230 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 166 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1223 | 0.040 |
Why?
| | Societies, Medical | 1 | 2023 | 703 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 8 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 43 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 41 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 357 | 0.040 |
Why?
| | Risk | 1 | 2022 | 853 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 502 | 0.040 |
Why?
| | Time Factors | 2 | 2021 | 6412 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 525 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 100 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 418 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 502 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 344 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 291 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Washington | 1 | 2008 | 141 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 151 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 43 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 140 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 262 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 369 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 157 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 246 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 119 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 497 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 900 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 5255 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 299 | 0.040 |
Why?
| | Mental Health | 1 | 2023 | 568 | 0.040 |
Why?
| | Weight Loss | 1 | 2022 | 655 | 0.040 |
Why?
| | Odds Ratio | 1 | 2010 | 996 | 0.040 |
Why?
| | Viral Load | 1 | 2019 | 419 | 0.040 |
Why?
| | Proctitis | 1 | 2016 | 4 | 0.040 |
Why?
| | Urogenital System | 1 | 2016 | 16 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2018 | 285 | 0.040 |
Why?
| | Anxiety | 1 | 2023 | 845 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2021 | 556 | 0.040 |
Why?
| | Latin America | 1 | 2016 | 74 | 0.040 |
Why?
| | Population Surveillance | 1 | 2019 | 413 | 0.040 |
Why?
| | Prisoners | 1 | 2008 | 128 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 245 | 0.040 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 155 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 125 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 726 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2010 | 523 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 131 | 0.030 |
Why?
| | Echocardiography | 1 | 2018 | 556 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 357 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 450 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 165 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 623 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 556 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 244 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 910 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1570 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2179 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 756 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3003 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 827 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 842 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1222 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2874 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3171 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1781 | 0.030 |
Why?
| | Communication | 1 | 2018 | 761 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1440 | 0.030 |
Why?
| | Health Promotion | 1 | 2008 | 691 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3588 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2566 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1810 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2746 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1208 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 269 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 781 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|